ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers

Vital Therapies, Inc. (VTI), a development stage company targeting liver disease, announced patient enrollment has begun for a randomized, controlled, multi-center, Phase 2 clinical trial that will study the Extracorporeal Liver Assist Device (ELAD) as a treatment for patients with Acute Liver Failure (ALF) under three protocols. The study is open for enrollment at seven U.S. sites, which will be expanded to 15 sites in the U.S. and Europe during the first half of 2009. Six patients have already been enrolled in the first protocol and four patients have been treated under the emergency use Expanded Access regulations.

This trial expands on prior results from phase 1 and...

Want to see the full article?

• Purchase this article for only $3.00